ALFA Finder| Revenue growth | 9% YoY operating revenue growth; 11% total revenue growth. |
|---|---|
| Margins | EBITDA margin at 22%; Core EBITDA margin at 29%. |
| Order book | Research Services continuing to secure new customers and contracts. |
| Demand visibility | Strong demand in North America for Biosimilars; GLP-1 momentum in EU. |
| Management confidence | High; citing robust investor confidence following $1 billion raised via QIPs. |
Growth
Consolidated Revenue grew 11% YoY; EBITDA up 21% to Rs 951 Cr; Generics revenue rose 24% YoY.
Outlook
Completed integration of Biocon Biologics; expect ~INR 300 Cr annual interest savings in FY27; new oncology launches planned.
Risks
CRDMO (Syngene) revenue declined 3% due to impact from a single large molecule client product.
Earnings Call filed with BSE, NSE: BIOCON. Summary written with AI assistance from the document.
Biocon Ltd: key numbers
- Share price
- ₹368.05
- Market cap
- ₹59,981 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 132.7×Sector 43.8×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Earnings Call Transcript: Key Takeaways
Q2 FY27 group revenue grew 2% YoY, with about 5% (~$20M) deferred to Q3 by a one-off shipment timing issue. Management guides a stronger H2 but gave no hard H2 numbers.
Biocon Management Change
Biocon's board recorded the resignation of Chief Technology Officer Mandar Ghatnekar, effective 31 December 2026. Mukesh Rathi is appointed CTO, effective 1 January 2027.
Biocon Other Announcement
Biocon Limited informed the Exchange of shareholder communications regarding the withholding of FY 2025-26 final dividends for missing mandatory KYC and bank details.
Biocon Investor Presentation: Key Takeaways
Q2 FY27 revenue from operations ₹4,389 Cr (+2% YoY), EBITDA ₹865 Cr (20% margin vs 22%), reported PAT ₹41 Cr (−52% YoY). Management expects a stronger H2.
Biocon Results Update
Biocon reported Q2FY27 consolidated total income of ₹4,423 crore with EBITDA at ₹865 crore. Net profit was ₹41 crore as Biopharma revenue grew 5% YoY.
Biocon Q2 FY27 Results: Net Profit ₹56.7 Cr, Down 57.3% YoY
Biocon Ltd reported revenue from operations of ₹4,389 Cr (+2.2% YoY) and net profit of ₹56.7 Cr (-57.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹56.7 Cr · -57.3% YoY